Diabetes Drug Does Not Increase Risk of Heart Failure
People that have diabetes and take the trug Alogliptin will no longer have to worry about the risk of heart failure or heart disease thanks to a new study. The study was performed by Dr. William White, professor of medicine and chief of the Calhoun Cardiology Center Division of Hypertension and Clinical Pharmacology at UConn Health. The study was published to the British medical journal, The Lancet.
In the study, the researcher looked at data from a global clinical trial known as EXAMINE, which is an acronym for “Examination of Cardiovascular Outcomes: Alogliptin vs. Standard of Care in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome.” Regulatory agencies require that a comprehensive evaluation of new diabetic therapies be performed. The analysis indicated that Alogliptin was safe for patients with Type 2 diabetes that were considered to be at high risk of developing a cardiovascular condition. Even in patients that had heart failure previously, there was no increase in hospitalization.
Type 2 diabetes patients have a known risk of mortality due to heart disease and according to data from the World Health Organization, heart disease makes up roughly 50 to 80 percent of the deaths among diabetics.